# Hepatocellular Carcinoma Surveillance

> HCC surveillance for NEET-SS Gastroenterology: six-monthly ultrasound with AFP, LI-RADS diagnosis, BCLC treatment tiers and transplant criteria.

- Canonical URL: https://prepelephant.com/topics/neet-ss/medical-gastroenterology/hepatocellular-carcinoma-surveillance
- Exam / course: NEET-SS · Subject: Medical Gastroenterology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Hepatocellular Carcinoma Surveillance", PrepElephant, https://prepelephant.com/topics/neet-ss/medical-gastroenterology/hepatocellular-carcinoma-surveillance

## Direct answer

Every six months, with ultrasound and alpha-fetoprotein, for every patient with compensated Child A or B cirrhosis who would accept curative treatment if cancer were found — that is the surveillance standard, and adding AFP to ultrasound measurably improves sensitivity over ultrasound alone. Non-cirrhotic hepatitis B patients qualify by risk: Asian men over 40, Asian women over 50, Africans over 20, a family history of HCC, or high viral replication with fibrosis. A nodule under 1 cm on ultrasound is re-imaged at 3–4 months rather than worked up; a nodule of 1 cm or more undergoes multiphase contrast CT or MRI, where the LI-RADS major criteria — arterial phase hyperenhancement plus washout, capsule, or threshold growth — make HCC a radiological diagnosis in a cirrhotic liver, no biopsy required. Treatment then follows BCLC biology: resection or ablation for early disease, transplant within Milan criteria, chemoembolisation for intermediate, and systemic therapy for advanced.

## What you must remember

- **Who to survey:** cirrhosis Child A/B (and decompensated patients listed for transplant, by transplant-programme logic); non-cirrhotic HBV meeting high-risk criteria; selected F3 NASH and HCV-cured patients with advanced fibrosis remain under surveillance — the fibrosis, not the virological status, carries the risk.
- **Modality and interval:** abdominal ultrasound with serum AFP every 6 months — the semiannual clock is anchored to tumour doubling times; interval variability beyond 2 months on either side degrades the whole programme.
- **Nodule algorithm:** under 1 cm — repeat ultrasound at 3–4 months (most are not HCC); 1 cm or more — multiphase CT or MRI with extracellular or hepatobiliary contrast, read to LI-RADS.
- **LI-RADS anchors:** LR-5 (definite HCC) requires arterial phase hyperenhancement with at least one major feature (washout, capsule appearance, threshold growth — 50 per cent size increase within 6 months) in a 10 mm or larger observation; LR-M (targetoid) suggests non-HCC malignancy and changes the pathway toward biopsy.
- **Biopsy exceptions:** imaging-diagnosed HCC in cirrhosis needs no tissue; biopsy is reserved for indeterminate lesions, non-cirrhotic livers, or when management (including transplant exception points) demands histology.
- **Curative tier:** surgical resection for single tumours with preserved liver function and clinically significant portal hypertension excluded (HVPG under 10 mmHg or surrogate non-invasive markers); thermal ablation (radiofrequency or microwave) for tumours 2–3 cm or less, where it rivals resection; transplant within Milan — one lesion 5 cm or less, or up to three lesions each 3 cm or less, no vascular invasion or extrahepatic spread — with down-to-Milan bridging therapy while waiting.
- **Intermediate and advanced tiers:** transarterial chemoembolisation (TACE) for multifocal disease preserved liver function without invasion; systemic therapy for advanced disease — atezolizumab plus bevacizumab as the modern first-line standard in suitable patients, with lenvatinib or sorafenib where immunotherapy is unsuitable and second-line options including regorafenib and ramucirumab (AFP 400 or more).
- **AFP's second job:** a rising AFP on serial surveillance is itself a trigger for multiphase imaging even with a bland ultrasound — dynamic risk, not a single threshold.
- **Indian practice note:** hepatitis B remains a dominant aetiology alongside alcohol and increasingly NASH; ultrasound quality varies widely between centres, and programme discipline — the 6-month recall system — is what separates surveillance from sporadic scanning.

## A worked surveillance-to-treatment case

A 61-year-old with hepatitis B cirrhosis, Child A6, platelets 118, has his 6-monthly ultrasound show a 1.8 cm right lobe nodule; AFP rises from 9 to 96. Multiphase MRI: arterial hyperenhancement with washout and capsule — LR-5, HCC by imaging. Staging: single tumour, preserved liver function, no portal hypertension by non-invasive criteria — BCLC stage 0/A, and the options are resection versus ablation versus transplant assessment. At 1.8 cm with an unfavourable location near the gallbladder fossa, radiofrequency ablation carries equivalent recurrence-free survival to resection at this size in many series, but his young age, solitary lesion and compensated status keep resection on the table; transplant evaluation runs in parallel given hepatitis B aetiology. Had the same lesion arrived in a Child C liver, the answer would have been transplant-first with bridging ablation; had there been five bilobar nodules with a patent portal vein, TACE; had there been vascular invasion or distant spread, systemic therapy. One lesion, four correct answers, decided by liver function, tumour burden and performance status — the BCLC triad.

## Where students slip

The classic errors: biopsying an LR-5 lesion in a cirrhotic liver (imaging is diagnostic; biopsy adds risk without changing management); working up a sub-centimetre nodule with multiphase CT (the answer is 3–4-month rescan); abandoning surveillance after successful antiviral therapy or HCV cure (advanced fibrosis still generates HCC); and quoting Milan from memory with the vascular-invasion clause omitted. The half-remembered numbers cost marks: 5 cm single, 3 cm multiple up to three, 50-per-cent threshold growth in 6 months, AFP 400 for ramucirumab eligibility.

## Frequently asked questions

### Who qualifies for hepatocellular carcinoma surveillance?

Patients with Child A/B cirrhosis who are transplant or treatment candidates; high-risk non-cirrhotic hepatitis B patients (Asian men over 40, Asian women over 50, Africans over 20, family history); and selected patients with advanced fibrosis.

### What imaging criteria diagnose HCC without biopsy in cirrhosis?

LI-RADS LR-5: arterial phase hyperenhancement in a 10 mm or larger observation with washout, capsule, or threshold growth on multiphase CT or MRI.

### How is a nodule under 1 cm on surveillance ultrasound handled?

Repeat ultrasound at 3–4 months, because most small nodules are not HCC; persistence or growth prompts multiphase imaging.

### What are the Milan transplant criteria?

A single tumour 5 cm or less, or up to three tumours each 3 cm or less, without vascular invasion or extrahepatic disease — with no size-related upper limit on overall burden beyond these.

### Which therapy suits intermediate-stage HCC?

Transarterial chemoembolisation for multifocal unresectable disease with preserved liver function and patent portal veins; systemic therapy follows on progression or vascular invasion.